Cullinan Oncology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cullinan Oncology generated cash of -$134,275,000, which is less than the previous year. Cash used in financing activities reached the amount of $40,751,000 last year. Net change in cash is therefore -$57,718,000.
Cash Flow
| 2018 | -13.54M | -261K | -29K |
|---|---|---|---|
| 2019 | -20.89M | -35.4M | 85.71M |
| 2020 | -29.77M | -5.42M | 140.14M |
| 2021 | -43.43M | -333.77M | 268.78M |
| 2022 | -126.66M | 248.97M | -25.93M |
| 2023 | -134.27M | 35.80M | 40.75M |
CGEM Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 156.15M | 59.77M | 168.19M | 63.25M | 33.83M | 47.67M |
Operating activities | ||||||
Net income | -153.16M | 109.19M | -67.48M | -59.45M | -21.65M | -14.18M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 310K | 93K | 53K | 62K | 70K | 43K |
Stock-based compensation expense | 30.43M | 27.95M | 24.37M | 14.91M | 17K | 0 |
| Deferred income tax benefit | 30.43M | 27.95M | 24.37M | 14.91M | 17K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -167K | -509K | -4.83M | 5.58M | 639K | 225K |
Cash generated by operating activities | -134.27M | -126.66M | -43.43M | -29.77M | -20.89M | -13.54M |
Investing activities | ||||||
Purchases Of Investments | -373.38M | -377.91M | -525.81M | -69.76M | -35.38M | 0 |
Investments In Property Plant And Equipment | -208K | -1.13M | -589.22K | -10K | -20K | -261K |
Acquisitions Net | -36.01K | 275M | 923K | 1.45M | 0 | 0 |
Cash generated by investing activities | 35.80M | 248.97M | -333.77M | -5.42M | -35.4M | -261K |
Financing activities | ||||||
Common Stock Issued | 38.38M | 6.02K | 267.26M | 140.14M | 85.71M | 1K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -213K | -378K | -21K |
Repayments of term debt | 1.82M | -2.2M | 0 | 0 | 0 | 0 |
Cash used in financing activities | 40.75M | -25.93M | 268.78M | 140.14M | 85.71M | -29K |
Net Change In Cash | -57.71M | 96.37M | -108.42M | 104.94M | 29.41M | -13.83M |
Cash at end of period | 98.43M | 156.15M | 59.77M | 168.19M | 63.25M | 33.83M |
| Data source | Data source | Data source | Data source |